152 related articles for article (PubMed ID: 12199802)
1. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism.
Pullarkat V; Ngo M; Iqbal S; Espina B; Liebman HA
Br J Haematol; 2002 Sep; 118(4):1166-9. PubMed ID: 12199802
[TBL] [Abstract][Full Text] [Related]
2. Antiphospholipid antibodies and venous thromboembolism.
Ginsberg JS; Wells PS; Brill-Edwards P; Donovan D; Moffatt K; Johnston M; Stevens P; Hirsh J
Blood; 1995 Nov; 86(10):3685-91. PubMed ID: 7579334
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival.
Artım-Esen B; Çene E; Şahinkaya Y; Erdugan M; Oğuz E; Gül A; Öcal L; İnanç M
Lupus; 2019 Oct; 28(12):1480-1487. PubMed ID: 31558101
[TBL] [Abstract][Full Text] [Related]
4. [Antiphospholipid antibodies as risk factor for venous thromboembolism].
Windyga J
Pol Arch Med Wewn; 2002 Nov; 108(5):1065-70. PubMed ID: 12685247
[TBL] [Abstract][Full Text] [Related]
5. Is the determination of anti-beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome?
Hsieh K; Knöbl P; Rintelen C; Kyrle PA; Quehenberger P; Bialonczyk C; Partsch H; Lechner K; Pabinger I
Br J Haematol; 2003 Nov; 123(3):490-5. PubMed ID: 14617012
[TBL] [Abstract][Full Text] [Related]
6. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus.
Nojima J; Kuratsune H; Suehisa E; Kawasaki T; Machii T; Kitani T; Iwatani Y; Kanakura Y
Br J Haematol; 2002 Aug; 118(2):577-83. PubMed ID: 12139749
[TBL] [Abstract][Full Text] [Related]
7. [Antiphospholipid syndrome and stroke].
Kitagawa Y
Rinsho Shinkeigaku; 2005 Nov; 45(11):852-5. PubMed ID: 16447744
[TBL] [Abstract][Full Text] [Related]
8. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus.
Nojima J; Kuratsune H; Suehisa E; Futsukaichi Y; Yamanishi H; Machii T; Kitani T; Iwatani Y; Kanakura Y
Br J Haematol; 2001 Sep; 114(3):647-54. PubMed ID: 11552993
[TBL] [Abstract][Full Text] [Related]
9. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees.
Yusuf HR; Hooper WC; Grosse SD; Parker CS; Boulet SL; Ortel TL
Thromb Res; 2015 Jan; 135(1):50-7. PubMed ID: 25456001
[TBL] [Abstract][Full Text] [Related]
10. Clinical and therapeutic aspects associated to phospholipid binding antibodies (lupus anticoagulant and anticardiolipin antibodies).
Ordi-Ros J; Pérez-Pemán P; Monasterio J
Haemostasis; 1994; 24(3):165-74. PubMed ID: 7988946
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolic events during warm autoimmune hemolytic anemia.
Audia S; Bach B; Samson M; Lakomy D; Bour JB; Burlet B; Guy J; Duvillard L; Branger M; Leguy-Seguin V; Berthier S; Michel M; Bonnotte B
PLoS One; 2018; 13(11):e0207218. PubMed ID: 30408135
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.
Neville C; Rauch J; Kassis J; Chang ER; Joseph L; Le Comte M; Fortin PR
Thromb Haemost; 2003 Jul; 90(1):108-15. PubMed ID: 12876633
[TBL] [Abstract][Full Text] [Related]
13. Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies.
Proven A; Bartlett RP; Moder KG; Chang-Miller A; Cardel LK; Heit JA; Homburger HA; Petterson TM; Christianson TJ; Nichols WL
Mayo Clin Proc; 2004 Apr; 79(4):467-75. PubMed ID: 15065611
[TBL] [Abstract][Full Text] [Related]
14. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with autoimmune hemolytic anemia.
Ho G; Brunson A; Keegan THM; Wun T
Blood Cells Mol Dis; 2020 Mar; 81():102388. PubMed ID: 31805473
[TBL] [Abstract][Full Text] [Related]
15. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458
[TBL] [Abstract][Full Text] [Related]
16. Risk of thromboembolism in patients with idiopathic autoimmune hemolytic disease and antiphospholipid antibodies: results from a prospective, case-control study.
Bongarzoni V; Annino L; Roveda A; Amendolea MA; Tirindelli MC; Avvisati G
Haematologica; 2005 May; 90(5):711-3. PubMed ID: 15929203
[TBL] [Abstract][Full Text] [Related]
17. Anti beta 2 glycoprotein I antibodies: detection and association with thrombosis.
Martinuzzo ME; Forastiero RR; Carreras LO
Br J Haematol; 1995 Feb; 89(2):397-402. PubMed ID: 7873391
[TBL] [Abstract][Full Text] [Related]
18. [Prevalence of lupus anticoagulant, autoimmune hemolysis, thrombocytopenia and disorders of platelet function in unselected patients with SLE].
Söhngen D; Specker C; Wehmeier A; Kiefel V; Rathmer L; Söhngen R; Schneider W
Beitr Infusionsther; 1992; 30():469-73. PubMed ID: 1284763
[TBL] [Abstract][Full Text] [Related]
19. Antibody profiles for the diagnosis of antiphospholipid syndrome.
Pengo V; Biasiolo A; Pegoraro C; Cucchini U; Noventa F; Iliceto S
Thromb Haemost; 2005 Jun; 93(6):1147-52. PubMed ID: 15968401
[TBL] [Abstract][Full Text] [Related]
20. Antibodies against phospholipids and beta 2-glycoprotein I increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus.
Wahl DG; De Maistre E; Guillemin F; Regnault V; Perret-Guillaume C; Lecompte T
QJM; 1998 Feb; 91(2):125-30. PubMed ID: 9578894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
